Prevalence and clinical associations of CXCR4-using HIV-1 among treatment-naive subtype c-infected women in botswana

Journal of Acquired Immune Deficiency Syndromes

Volumn 57, Issue 1, 2011, Pages 46-50

  Lin, Nina H ^a,b   Smeaton, Laura M ^c,d   Giguel, Françoise ^a,e   Novitsky, Vladimir ^c,d   Moyo, Sikhulile ^d   Mitchell, Rebecca M ^c,d   Makhema, Joseph ^d   Essex, Myron ^c,d   Lockman, Shahin ^b,c,d,e   Kuritzkes, Daniel R ^b,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

AIDS; antiretroviral therapy; CCR5; CXCR4; HIV 1 tropism; subtype C

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4;

ARTICLE; BOTSWANA; CD4 LYMPHOCYTE COUNT; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PREVALENCE; PRIORITY JOURNAL;

ADULT; BOTSWANA; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; PREVALENCE; RECEPTORS, CXCR4; RNA, VIRAL;

EID: 79955038304     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318214fe27     Document Type: Article

References (37)

1. Connor RI, Sheridan KE, Ceradini D, et al. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med. 1997;185:621-628. (Pubitemid 27098147)
2. Koot M, Keet IP, Vos AH, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med. 1993;118:681-688. (Pubitemid 23118038)
3. Schuitemaker H, Koot M, Kootstra NA, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol. 1992;66: 1354-1360.
4. Bozzette SA, McCutchan JA, Spector SA, et al. A cross-sectional comparison of persons with syncytium - and non-syncytium-inducing human immunodeficiency virus. J Infect Dis. 1993;168:1374-1379. (Pubitemid 23344894)
5. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis. 1994;169:968-974. (Pubitemid 24303213)
6. Abebe A, Demissie D, Goudsmit J, et al. HIV-1 subtype C syncytium - and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. AIDS. 1999;13:1305-1311. (Pubitemid 29408444)
7. Cecilia D, Kulkarni SS, Tripathy SP, et al. Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India. Virology. 2000;271:253-258. (Pubitemid 30461303)
8. Bjorndal A, Sonnerborg A, Tscherning C, et al. Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS Res Hum Retroviruses. 1999;15:647-653. (Pubitemid 29205668)
9. Ping LH, Nelson JA, Hoffman IF, et al. Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J Virol. 1999;73:6271-6281. (Pubitemid 29327803)
10. van Rensburg EJ, Smith TL, Zeier M, et al. Change in co-receptor usage of current South African HIV-1 subtype C primary isolates. AIDS. 2002;16: 2479-2480. (Pubitemid 35471696)
11. Cilliers T, Nhlapo J, Coetzer M, et al. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol. 2003;77:4449-4456. (Pubitemid 36350986)
12. Papathanasopoulos MA, Cilliers T, Morris L, et al. Full-length genome analysis of HIV-1 subtype C utilizing CXCR4 and intersubtype recombinants isolated in South Africa. AIDS Res Hum Retroviruses. 2002;18:879-886. (Pubitemid 35034670)
13. Tien PC, Chiu T, Latif A, et al. Primary subtype C HIV-1 infection in Harare, Zimbabwe. J Acquir Immune Defic Syndr Hum Retrovirol. 1999; 20:147-153. (Pubitemid 29063712)
14. Johnston ER, Zijenah LS, Mutetwa S, et al. High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol. 2003;77:7682-7688. (Pubitemid 36734540)
15. Connell BJ, Michler K, Capovilla A, et al. Emergence of X4 usage among HIV-1 subtype C: evidence for an evolving epidemic in South Africa. AIDS. 2008;22:896-899. (Pubitemid 351563840)
16. Michler K, Connell BJ, Venter WD, et al. Genotypic characterization and comparison of full-length envelope glycoproteins from South African HIV type 1 subtype C primary isolates that utilize CCR5 and/or CXCR4. AIDS Res Hum Retroviruses. 2008;24:743-751. (Pubitemid 351748781)
17. Shapiro RL, Thior I, Gilbert PB, et al. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS. 2006;20:1281-1288. (Pubitemid 44030377)
18. Thior I, Lockman S, Smeaton LM, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA. 2006;296:794-805. (Pubitemid 44223103)
19. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med. 2007; 356:135-147. (Pubitemid 46089674)
20. Lin NH, Negusse DM, Beroukhim R, et al. The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates. J Virol Methods. 2010;169:39-46.
21. Tersmette M, de Goede RE, Al BJ, et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol. 1988;62:2026-2032.
22. Shepherd JC, Jacobson LP, Qiao W, et al. Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study. J Infect Dis. 2008;198:1104-1112.
23. Choge I, Cilliers T, Walker P, et al. Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. AIDS Res Hum Retroviruses. 2006;22:458-465. (Pubitemid 43787772)
24. Coetzer M, Cilliers T, Ping LH, et al. Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. Virology. 2006;356:95-105. (Pubitemid 44750034)
25. Ndung'u T, Sepako E, McLane MF, et al. HIV-1 subtype C in vitro growth and coreceptor utilization. Virology. 2006;347:247-260.
26. Tressler R, Greenacre A, Rajicic N, et al. Distribution of HIV-1 coreceptor tropism among individuals in India infected with clade C HIV-1. 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Cape Town, South Africa; 2009.
27. Brumme ZL, Goodrich J, Mayer HB, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis. 2005;192:466-474. (Pubitemid 41023125)
28. Furrer H, Wendland T, Minder C, et al. Association of syncytium-inducing phenotype of HIV-1 with CD4 cell count, viral load and sociodemographic characteristics. AIDS. 1998;12:1341-1346. (Pubitemid 28330727)
29. Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis. 2005;191:866-872. (Pubitemid 40349800)
30. Melby T, Despirito M, Demasi R, et al. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis. 2006;194:238-246. (Pubitemid 44087196)
31. Wilkin TJ, Su Z, Kuritzkes DR, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis. 2007;44:591-595. (Pubitemid 46233265)
32. Fatkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008; 359:1442-1455.
33. Delobel P, Sandres-Saune K, Cazabat M, et al. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2005;38:382-392. (Pubitemid 40381547)
34. Hunt PW, Harrigan PR, Huang W, et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis. 2006;194:926-930. (Pubitemid 44454078)
35. Su Z, Gulick RM, Krambrink A, et al.Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J Infect Dis. 2009;200:1724-1728.
36. Herbeck JT, Lyagoba F, Moore SW, et al. Prevalence and genetic diversity of HIV type 1 subtypes A and D in women attending antenatal clinics in Uganda. AIDS Res Hum Retroviruses. 2007;23: 755-760. (Pubitemid 46867475)
37. Kaleebu P, Nankya IL, Yirrell DL, et al. Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr. 2007;45: 28-33. (Pubitemid 46684440)